Additional Outcome of the Board Meeting
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma's Board meeting held on 22 May 2026 concluded with two key outcomes. First, the Board approved requests for reclassification of certain promoter group individuals from the 'Promoter Group' category to the 'Public' category, subject to regulatory approvals under SEBI Regulation 31A. This follows an earlier intimation dated 14 May 2026. Second, the Board approved and adopted a revised Code of Fair Disclosure for Unpublished Price Sensitive Information, effective 01 June 2026. The meeting was adjourned and resumed before concluding at 4:00 PM.
The reclassification of promoter group individuals to public shareholder status will reduce the disclosed promoter holding, potentially altering the promoter-to-public shareholding ratio. This is mildly negative for existing public shareholders as it increases the free-float, though no specific quantum of shares was disclosed.